Novartis
British baby’s death not caused by Zolgensma says Novartis
September 19, 2019Research and Development AveXis, Novartis, Zolgensma, spinal muscular atrophy
Swiss drugmaker Novartis have stated that a British baby’s death this year after getting Novartis’ gene therapy Zolgensma, was not …
Novartis’ Cosentyx has strong Phase 3 interim showing in axial spondyloarthritis
September 17, 2019Manufacturing and Production, Research and Development Cosentyx, Novartis, pharma
Novartis has highlighted new data from its ongoing Phase 3 trial into the efficacy and safety of itsinterleukin-17A inhibitor Cosentyx …
Novartis announce robust Phase 3 trials for ofatumumab in MS
September 16, 2019Research and Development, Sales and Marketing Aubagio, Novartis, multiple sclerosis
Novartis’ multiple sclerosis candidate has demonstrated strong results in its Phase 3 ASCLEPIOS trials meeting primary endpoints and slashing the …
Novartis’ Mayzent delays time wheelchair dependence by 4 years in secondary progressive multiple sclerosis
September 12, 2019Research and Development ECTRIMS 2019, Mayzent, Novartis, multiple sclerosis, pharma
Novartis has taken the opportunity at the 2019 Congress of The European Committee for Treatment and Research in Multiple Sclerosis …
4.5-year data confirms long-term efficacy of Novartis’ Aimovig in episodic migraine
September 9, 2019Research and Development, Sales and Marketing Aimovig, Novartis, migraine, pharma
Novartis has lifted the curtain on interim data from the 4.5-year mark of a five-year open-label treatment period (OLTP) investigating …
Novartis’ Lucentis secures European approval for infants with rare eye disease
September 6, 2019Medical Communications, Sales and Marketing Europe, Lucentis, Novartis, eye disease, pharma
Novartis has made the surprise announcement that its VEGF inhibitor Lucentis (ranibizumab) has been awarded marketing authorisation from the European …
Experimental Novartis drug secures FDA Breathrough designation for rare lung cancer
September 6, 2019Medical Communications, Sales and Marketing Cancer, Novartis, capmatinib, lung cancer, pharma
Novartis is celebrating the acceptance of its experimental cancer drug capmatinib by the FDA onto an accelerated review pathway, securing …
Novartis’ ofatumumab outclasses Sanofi’s Aubagio at Phase 3 in relapsing multiple sclerosis
September 3, 2019Manufacturing and Production, Research and Development Arzerra, Genmab, Novartis, multiple sclerosis, pharma
New data from two Phase 3 studies have indicated that Novartis’ ofatumumab outperformed Sanofi Genzyme’s Aubagio (teriflunomide) in the treatment …
Novartis’ Entresto narrowly misses Phase 3 goal in heart failure patients
September 2, 2019Research and Development, Sales and Marketing Entresto, Novartis, heart failure, pharma
New Phase 3 data for Novartis’ Entresto (sacubitril/valsartan) have been released, showing that the therapy narrowly missed its primary endpoint …
Genmab & Novartis’ ofatumumab tops Sanofi’s Aubagio in relapsing multiple sclerosis
August 30, 2019Medical Communications, Research and Development Genmab, Novartis, multiple sclerosis, ofatumumab, pharma
Genmab and Novartis have revealed positive new data from two Phase 3 studies of its monthly subcutaneous formulation of ofatumumab …
Working Life: Linda Armstrong, Global Head, Respiratory Development Unit at Novartis
August 27, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Working Life, feature, pharma
Linda Armstrong, Global Head, Respiratory Development Unit at Novartis.
Novartis exec pushed out over Zolgensma data scandal denies wrongdoing
August 21, 2019Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma
Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …
Novartis exec sold off shares before Zolgensma data scandal was revealed
August 19, 2019Sales and Marketing AveXis, Novartis, Shares, Zolgensma, pharma, stock market
An unnamed Novartis executive sold 925,400 Swiss francs (£778,665) worth of shares in the firm just weeks before the FDA …
Top Ten most popular articles on Pharmafile.com this week!
August 16, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Air pollution, CAR-T therapy, HIV, Kymriah, Medicare, Novartis, Yescarta, Zolgensma
Novartis’ faulty data scandal dominated the headlines this week, as the Swiss firm faced fierce backlash over covering up the …
Senate Finance Comittee Chairman, Chuck Grassley calls on Novartis to reveal details of data scandal
August 13, 2019Research and Development AveXis, Chuck Grassley, Novartis, Zolgensma, sfc
Chuck Grassley, Chairman of the Senate Finance Committee, has demanded that Novartis give up details on the faulty data scandal …
